Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
316 people get SYN articles and Market Currents by email alert.
Get email alerts on SYN »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
There are no Transcripts on SYN.
-
PR Newswire (Thu, 11:30AM)
-
PR Newswire (May 21, 2013)
-
PR Newswire (May 15, 2013)
-
PR Newswire (Apr 19, 2013)
-
PR Newswire (Apr 16, 2013)
-
PR Newswire (Mar 12, 2013)
-
PR Newswire (Feb 26, 2013)
-
PR Newswire (Feb 5, 2013)
-
PR Newswire (Jan 7, 2013)
-
PR Newswire (Dec 3, 2012)
-
PR Newswire (Nov 30, 2012)
-
PR Newswire (Nov 14, 2012)
-
PR Newswire (Nov 12, 2012)
-
PR Newswire (Oct 31, 2012)
-
PR Newswire (Oct 29, 2012)
-
PR Newswire (Oct 9, 2012)
SYN vs. ETF Alternatives
Company Description
Synthetic Biologics is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Synthetic Biologics is developing, or has partnered the development of, product candidates to treat pulmonary arterial... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Tuesday, April 30, 12:46 PM
Midday top 10 gainers: TTHI +45%. PTIE +26%. DRRX +26%. MTOR +23%. MGAM +20%. OIS +16%. GIB +14%. HGSH +15%. ARWR +13%. TXRH +13%.
Midday top 10 losers: DCTH -44%. AVEO -26%. NUAN -18%. AOSL -18%. PBI -16%. AEIS -13%. MSTR -10%. ANV -10%. ELTK -10%. SYN -10%. Comment! [On the Move] - Tuesday, April 16, 3:05 PM Synthetic Biologics (SYN -1.2%) slips after reporting its year-end financials this morning, reiterating its focus on strengthening its infectious disease portfolio. The company says it's raised capital this year that includes $10.1M in net proceeds from the sale of about 6.8M shares. Other income was $15K, compared to an expense of $1.7M for the same period in 2011. Comment! [Healthcare, Earnings, On the Move]
- Thursday, April 4, 4:00 PM Synthetic Biologics (SYN +4.3%), which was trading lower on the session, jumps after saying a patent issued to the University of California "includes claims to the use of [the company's] drug candidate Trimesta in combination" with Copaxone, Teva's (TEVA -0.8%) annual $14B selling multiple sclerosis drug. 1 Comment [Healthcare, On the Move]
- Friday, December 2, 2011, 2:22 PM Microcap biotech developer Adeona Pharmaceuticals (AEN) continues to rally today, up another 19% after reporting positive Phase I/II results on Wednesday for its clinical collaborator for Lou Gehrig's disease. Comment! [On the Move, Healthcare]
- Wednesday, November 30, 2011, 3:23 PM Shares of microcap biotech developer Adeona Pharmaceuticals (AEN) soar over 23% after reporting successful results from its pilot Phase I/II safety study of oral high dose zinc therapy in ALS, also known as Lou Gehrig's disease. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
timtrading123
Stochastic Crossover $AAN,$ACCO,$ACXM,$SYN,$AEP,$AEZS,$ALB,$AAMRQ.PK http://bit.ly/qK7RMK - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Chemistfrog
Adeona (AMEX: SYN) prescription food for Alzheimer's trial completes in March. Data will be presented mid-April. Bounced off 1.05! - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Roy Manning III
SYN ; possible value play. Recent deal and pipeline all for $25 million market cap. Company finds and patents second uses for existing drugs - View all 0 replies
LATEST REPLIES